scholarly article | Q13442814 |
P356 | DOI | 10.1093/CKJ/SFT065 |
P8608 | Fatcat ID | release_h5iupo6okzcvlhcw4l4fplm4gi |
P932 | PMC publication ID | 3888095 |
P698 | PubMed publication ID | 24422172 |
P5875 | ResearchGate publication ID | 259722696 |
P50 | author | Rodney D. Gilbert | Q41580948 |
Timothy H J Goodship | Q115122955 | ||
P2093 | author name string | Louise K Stanley | |
Steven A Hardy | |||
Darren J Fowler | |||
Elizabeth M Angus | |||
P2860 | cites work | Atypical hemolytic uremic syndrome | Q21202864 |
Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome | Q24634697 | ||
The development of atypical hemolytic uremic syndrome depends on complement C5 | Q28300378 | ||
Haemolytic uraemic syndrome following chemotherapy for an unusual germ-cell tumour | Q28370405 | ||
Complement-dependent clearance of apoptotic cells by human macrophages | Q30442812 | ||
Chemotherapy-related hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx | Q33338736 | ||
A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders | Q33371578 | ||
Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults | Q33405246 | ||
Thrombotic Microangiopathy and Renal Failure Associated with Antineoplastic Chemotherapy | Q33476240 | ||
Cisplatin-associated hemolytic uremic syndrome | Q33491119 | ||
Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. | Q33499022 | ||
Role of complement and perspectives for intervention in ischemia-reperfusion damage. | Q37831329 | ||
Nephrotoxicity of combined treatment with cisplatin and gentamicin in the guinea pig: glomerular injury findings | Q46157733 | ||
Carboplatin-associated thrombotic microangiopathic hemolytic anemia. | Q55485142 | ||
Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour | Q83135449 | ||
P433 | issue | 4 | |
P304 | page(s) | 421-425 | |
P577 | publication date | 2013-08-01 | |
P1433 | published in | Clinical kidney journal / an academic journal of the ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) | Q26842221 |
P1476 | title | Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab | |
P478 | volume | 6 |
Q26750692 | Critical appraisal of eculizumab for atypical hemolytic uremic syndrome |
Q33783126 | Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome |
Q27003211 | Current treatment of atypical hemolytic uremic syndrome |
Q33411956 | Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement |
Q92134406 | Eculizumab in chemotherapy-induced thrombotic microangiopathy |
Q42858176 | Factors influencing treatment of atypical hemolytic uremic syndrome. |
Q37032691 | The Genetics of Ultra-Rare Renal Disease |
Q33432099 | The alternative pathway of complement and the thrombotic microangiopathies |
Q42368351 | Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. |
Q36241014 | Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients |
Search more.